National Research Ethics Committee

NREC-CT Meeting

13th November 2024

Attendance

Name	Role
Prof David Brayden	Chairperson, NREC-CT D
Dr Christina Skourou	Deputy Chairperson, NREC-CT D
Prof Andrew Green	Committee Member, NREC-CT D
Prof Cathal Walsh	Committee Member, NREC-CT D
Prof Deirdre Murray	Committee Member, NREC-CT D
Dr Geraldine O'Dea	Committee Member, NREC-CT D
Prof Lina Zgaga	Committee Member, NREC-CT D
Ms Deirdre McLoughlin	Committee Member, NREC-CT D
Dr Mary McDonnell Naughton	Committee Member, NREC-CT D
Ms Chanel Watson	Committee Member, NREC-CT D
Dr Jeff Moore	Committee Member, NREC-CT D
Ms Aileen Sheehy	Programme Manager, National Office for RECs
Dr Laura Mackey	Programme Officer, National Office for RECs
Dr Susan Quinn	Programme Manager, National Office for RECs
Ms Patricia Kenny*	Project Officer, National Office for RECs
Jane Bryant	Programme Officer, National Office for RECs
Ciaran Horan	Administrative Assistant, National Office for RECs

*Drafted minutes

Apologies: Geraldine O'Sullivan Coyne, Gerry Daly and David Smith

Quorum for decisions:

Agenda

- Welcome & Apologies
- 2024-516247-62-00
- 2023-507853-13-00
- 2024-514208-15-00
- 2023-510384-36-00 SM-1
- 2024-511378-60-00 SM-1
- 2022-502548-12-00 SM-5
- 2023-503697-21-01 SM-10
- 2022-501374-19-00 SM-2
- 2023-506241-30-00 SM-17
- AOB

- The Chair welcomed the NREC-CT D.
  - The minutes from the previous NREC-CT D meeting on 9th October were approved.
  - The NREC Business Report was discussed and noted.

Applications

2024-516247-62-00

Institutions: St James's Hospital

Study title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Request for Further Information

- **Additional Information Required**

Part II Considerations

1. **Compliance with national requirements on data protection**
   - No considerations raised by NREC
2. **Compliance with use of biological samples**
   - No considerations raised by NREC
3. **Financial arrangements**
   - The NREC-CT noted that payments will be made to participants and requested that these payments are equitable across all study participants without condition and regardless of their level of participation. The NREC-CT deemed that payments for the participants involved in optional sub-studies could put coercive pressure on the participants to take part in a sub-study which they might not otherwise take part in. The NREC-CT has requested that payments made to study participants for "time and inconvenience of completing the study electronic diary" or "time and the inconvenience of remaining at the study centre to participate" are ensured to be fair and equitable across all study participants without conditions, and clearly outlined in the PISCF.
4. **Proof of insurance**
   - No considerations raised by NREC
5. **Recruitment arrangements**
   - No considerations raised by NREC
6. **Subject information and informed consent form**
   - The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.
   - The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.

- The NREC-CT noted that there is variation in the number of participants to be recruited in Ireland listed in the documentation submitted, and requested that the planned recruitment number of participants in Ireland and in total is clarified, and that this information is added to all Participant Information and Consent Form documents on page 2 section “What is the purpose of this clinical research study?”
- The NREC-CT requested clarity on how long the screening visit and the Day 1 Visit 1 will take. In addition, clarity regarding how many times the participant will visit the study site during the 10-week screening phase is requested to be added to the PISCF in the relevant sections.
- The NREC-CT noted that the Main PISCF has used a bundled approach to consent in the Informed Consent Section of the PISCF and requested that a layered approach to consent is used (in that each consent item is listed and a box for participants to provide their initials is included alongside each consent item) in line with HSE policy. Please see HSE National Policy for Consent in Health and Social Care Research (V1.1, 2023) https://hseresearch.ie/wp-content/uploads/2023/02/HSE-National-Policy-for-Consent-in-Health-and-Social-Care-Research-compressed.pdf
- The NREC-CT noted that continuing access to the IMP may be available to participants under an open-label extension study as detailed on page 10. The NREC-CT requested that more clarity is provided in the PISCF on the option of continuing into the open-label extension study, for example but not limited to, what is an open label study, the limitations for joining, contacts points for more information.
- The NREC-CT notes that on page 11, pregnant participants are expected to provide information on the outcome of the pregnancy. The NREC-CT requests that this should be made more explicit, detailing what information will be requested, stored and access to that information, and that it is included as a separate Pregnancy PISCF.

7. Suitability of the clinical trial sites facilities

- No considerations raised by NREC

8. Suitability of the investigator

- No considerations raised by NREC

2023-507853-13-00

Institutions: Beaumont Hospital

Study title: I7P-MC-DSAG - An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Request for Further Information

- **Additional Information Required**

Part II Considerations

1. **Compliance with national requirements on data protection**

- No considerations raised by the NREC

2. **Compliance with use of biological samples**

- No considerations raised by the NREC

3. **Financial arrangements**

- No considerations raised by the NREC

4. **Proof of insurance**

- No considerations raised by the NREC

5. **Recruitment arrangements**

- The NREC-CT requested that the Doctor to patient letter be updated to clarify
    - that this is a Phase 2 clinical research study
    - to explicitly explain that patients randomised to the placebo arm will be off treatment
- The NREC-CT requested that the Doctor to doctor letter be updated to clarify
    - that there is a placebo arm on the study
    - to explicitly explain that patients randomised to the placebo arm will be off treatment
- The NREC-CT requested that the Flipchart be updated to provide a lay language explanation for the term Placebo.
- The NREC-CT were unclear if Social-1080x1080, Social-1200x628, Social Media and URL's documents will be used/available to Irish participants. Please clarify. If they will not be used in Ireland then please remove them from the submission.
- The NREC-CT were unclear if use of AcruianHealth or Synexus recruitment agency will be used/available to Irish participants. The Committee requested clarification on:
    - If it will be used/available in Ireland, the Committee requested clarification on how this system would work in Ireland. If it will not be used in Ireland then please remove the documentation relevant to this from the submission.
    - will this service bypass the referral system from the clinical team.
    - How will AcruianHealth or Synexus know which Irish participants to contact about the study.
    - How will Irish participants have consented to be contacted about this or other research studies

6. **Subject information and informed consent form**

- The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation
- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.

- The NREC-CT requests that the Main ICF-A, Main ICF-B and Main ICF-C be updated to include detail of the actual minimum amount of time participants on IV and SC will be monitored at the site following infusion.
- The NREC-CT requested that Main ICF-A pg. 9/10, Main ICF-B pg. 10 and Main ICF-C pg. 10 reference to HIV and Hepatitis "The results of your tests will be kept confidential and will only be shared (disclosed) as required by law" be updated to inform Irish participants that the study team are required to report any positive HIV, Hep test result to the relevant authority as they are mandatory notifiable diseases. (Infectious Diseases (Amendment) Regulations 2022 (S.I. No. 258 of 2022) May 2022).
- The NREC-CT noted the Main ICF-A pg. 23, Main ICF-B pg 23 and Main ICF-C pg 24 states "If you follow the directions of the study doctor and staff and you are physically injured due to any substance or procedure properly given under the plan for this study, the Sponsor will pay the medical expenses for the treatment of that injury if this is not covered by your medical insurance, by a government program, or by any other third party." The Committee advised that the participants medical insurance or Irish health service should not be expected to cover the costs of medical expenses in this situation.
- The NREC-CT requested that the Main ICF-A pg. 33, Main ICF-B pg. 33 and Main ICF-C pg 34 statement "You will be paid by ScoutPass, PayPal or bank transfer" be updated to clarify if it is the participant who can decide which option to be paid by.
- The NREC-CT requested that section on pg. 18 Main ICF-A, pg 19 Main ICF-B and Main ICF-C pg 20 Risks for Paediatric Participants be removed from the ICF as the trial doesn't have paediatric participants.
- The NREC-CT noted the Pregnant Partner Participant ICF pg 6 records both the participant number and participant initials. The Committee requested the Participant Initial be removed.
- The NREC-CT requested that the Pregnant Partner Participant ICF pg 6 be updated to change "I agree to my and my unborn child/newborn child's personal information as collected…" to "I agree to my and my unborn child/newborn child's pseudonymised information as collected".
- The NREC-CT noted that the Scout Email Communication is not geared towards an Irish audience and requested that it be updated to be relevant for Irish Participants and include an Irish contact number.
- The NREC-CT noted reference to autoinjector in Main ICF-A pg 19, Main ICF-B pg 20, Main ICF-C pg 21. This is the only reference to autoinjector being used in any of the other study documentation. Please update the ICF's to either remove reference to it or to provide more information about this.
- It was not clear to the NREC-CT if the number of colonoscopies and biopsies to be undertaken during the study are additional to what would normally be expected with this patient group. The Committee requested the Main ICF-A, Main ICF-B and Main ICF-C be updated to include details of this.
- The NREC-CT noted the Compliance with use of biological samples document section 4 refers to future use of samples for Exploratory Biomarker Research however it is not clear in the Main ICF's that the biomarker research referred is exploratory future research. The Committee requested that the Main ICF-A pg 10,

Main ICF-B pg 10 and Main ICF-C pg 11 be updated to clarify that biomarker research is exploratory and is limited to the drug/disease under study. . The Committee also requested that the consent forms on all the ICF's be updated to include a specific consent statement for this biomarker/future research limited to the disease, drug under study for participants to be able to explicitly consent to this.

7. **Suitability of the clinical trial sites facilities**

- No considerations raised by the NREC

8. **Suitability of the investigator**

- No considerations raised by the NREC

2024-514208-15-00

Institutions: Children's Health Ireland, Temple St

Study title: teACH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 years of age) with Achondroplasia

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required**

Part II Considerations

1. **Compliance with national requirements on data protection**

- No considerations raised by NREC

2. **Compliance with use of biological samples**

- No considerations raised by NREC

3. **Financial arrangements**

- No considerations raised by NREC

4. **Proof of insurance**

- No considerations raised by NREC

5. **Recruitment arrangements**

- The NREC-CT requested justification is provided for not including participants who lack capacity or who do not speak the national language, on the trial.

6. **Subject information and informed consent form**

- The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation
- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are

unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.

- The NREC-CT noted that the Consent Form and Participant Information sheet are separate documents. The Committee requested that the Participant Information Sheet and Consent Form be combined into one document.
- The NREC-CT noted that the Legal Age PIS pg 4 and Parent/Legal Guardian PIS pg. 4 refers to collection of race and ethnicity. In line with GDPR special category data requirements, the Committee requested justification regarding collection of race and ethnicity data. The Committee also requested that the ICF's be updated to include this justification in line with GDPR requirements.
- The NREC-CT noted that the only reference to patient travel vendor is in the consent form page 3. The Committee requested that both the Legal Age PIS and Parent/Legal Guardian PIS be updated to include detail of the travel vendor and how the travel arrangements will work.
- The NREC-CT requested that the PIS Assent be updated to explain the potential benefits of the study.

7. Suitability of the clinical trial sites facilities

- No considerations raised by NREC

8. Suitability of the investigator

- No considerations raised by NREC

2023-510384-36-00 SM-1

Institutions: Sligo University Hospital, University Hospital Galway, Cork University Hospital, University Hospital Limerick, St Vincent's University Hospital, Beaumont Hospital, St James's Hospital

Study title: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required**

Part II Considerations

9. Compliance with national requirements on data protection

- This document represents information already approved under CTD

10. Compliance with use of biological samples

- This document represents information already approved under CTD

11. Financial arrangements

- This document represents information already approved under CTD

12. Proof of insurance

- No considerations raised by NREC

13. Recruitment arrangements

- This document represents information already approved under CTD

14. Subject information and informed consent form

- The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation
- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
- The NREC-CT noted that the satellite site Sligo University Hospital will be utilised for participants who will be randomised into arm B-Lena treatment only. The NREC-CT requests that the PISCF should contain a statement advising participants that participants randomised to Arm B-Lena treatment would need to travel to a separate site from Galway University Hospital.
- The NREC-CT note the request in the cover letter which states: “In light of this comprehensive safety data and evolving trial needs, we propose allowing Sub-Investigators (Sub-Is) to consent participants when the PI is unavailable.” The NREC-CT approve this change.

15. Suitability of the clinical trial sites facilities

- Due to the travel and geographical nature of the trial sites and satellite site and the incidence of CRS in the SRI and SRI2 population, the NREC-CT recommends that participants recruited into the study are recruited as inpatients, specifically as the SmPC of Teclistamab recommends that patients during the step-up dosing phase should be instructed to remain within the proximity of a health care facility for 48hours.
- The NREC-CT noted that the site suitability document is signed by the principal investigator. As per the form signature section, this form should be signed by the Chief Executive Officer, Head of Clinic / Institution, Director of Research Clinical Director, or delegate at site.

16. Suitability of the investigator

- No considerations raised by NREC

2024-511378-60-00 SM-1

Institutions: Beaumont Hospital

Study title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Favourable

- **Additional Information Required**
- None

2022-502548-12-00 SM-5

Institutions: University Hospital Waterford, St James's Hospital

Study title: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With elapsed/Refractory Follicular or Marginal Zone Lymphoma

Dossiers Submitted: Part I & II

- NREC-CT Decision:

- Request for Further Information

- Additional Information Required

Part II Considerations

1. **Compliance with use of biological samples**
   - No considerations raised by NREC
2. **Subject information and informed consent form**
   - The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation
   - The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
   - The NREC-CT requested that the SIS and ICF Main Ireland FL pg 5 and SIS and ICF Main Ireland MZL pg 5 be updated to add a statement to inform participants that the study team are required to report any positive HIV, Hep A or Hep C test result to the relevant authority as they are mandatory notifiable diseases. (Infectious Diseases (Amendment) Regulations 2022 (S.I. No. 258 of 2022) May 2022)
   - The NREC-CT felt it was not clear to the participants if meningoencephalitis is a rare or very rare SE. The Committee requested that the SIS and ICF Main Ireland FL pg. 18 and SIS and ICF Main Ireland MZL pg. 16 "viral infection of the brain and its covering (meninges)" be updated to include a statement that some cases are fatal.

3. **Suitability of the clinical trial sites facilities**

- No considerations raised by NREC

4. **Suitability of the investigator**

- No considerations raised by NREC

2023-503697-21-01 SM-10

Institutions: Connolly Hospital, Our Lady of Lourdes Hospital, St Vincent's University Hospital

Study title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required**

Part II Considerations

1. **Subject information and informed consent form**

- The Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment. Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation
- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.
- The NREC-CT noted a contradiction in wording in SIS and ICF Main pg 24. Section 4.2 states that "Travel expenses associated with traveling to the appointments" will not be covered however Section 4.3 "Will the study sponsor reimburse you for any costs" refers to travel expenses including mileage, airfare and parking being paid. The Committee requested that this be corrected to be clear to participants.
- The NREC-CT requested that the GP letter be updated to provide clear instructions regarding the use of immunosuppressive treatments during the study for their patients.

2. **Suitability of the clinical trial sites facilities**

- No Considerations raised by NREC

3. **Suitability of the investigator**

- No Considerations raised by NREC

2022-501374-19-00 SM-2

Institutions: St James's Hospital

Study title: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Favourable

- **Additional Information Required**
- None

2023-506241-30-00 SM-17

Institutions: Tallaght University Hospital, St Vincent's University Hospital

Study title: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Dossiers Submitted: Part II

- **NREC-CT Decision:**
- Favourable

- **Additional Information Required**
- None

- AOB:
- Reminder about the upcoming NREC Forum